Group 5B: HER2-low & HER2-negative Breast Cancer; Targeted Therapies

Poster #1021: HER2-low status discordance between primary and recurrent/metastatic breast cancer in a large-scale cohort

Poster #1037: Association of C-MYC, MYC target gene, and unfolded protein response (UPR) expression with clinical benefit from the oral aurora kinase A (AURKA) inhibitor, alisertib (A), in combination with paclitaxel (P) compared with P alone in patients (Pts) with HER2-negative metastatic breast cancer (MBC)